Healios KK ( (JP:4593) ) has shared an announcement.
Healios K.K. has entered into a Master Collaboration Agreement and a License Option Agreement with Akatsuki Therapeutics to advance the research and development of its eNK cell therapies. This strategic partnership will allow Akatsuki to lead R&D activities and reduce Healios’ financial burden, with significant cost savings and a payment from Akatsuki. The collaboration aims to optimize resource use and target the global oncology market, enhancing Healios’ industry positioning.
More about Healios KK
Healios K.K. operates in the regenerative medicine industry, focusing on the development and manufacturing of iPSC-derived immune cell therapies, specifically eNK cells, for the treatment of cancer and other diseases.
YTD Price Performance: 32.77%
Average Trading Volume: 1,354,842
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen21.18B
See more insights into 4593 stock on TipRanks’ Stock Analysis page.